Kinestase (Cisapride)

Active Ingredient: Cisapride
Dosage: 10 mg
Route of Administration: Oral
Dosage Form: Tablets
Quantity per package: 30 tablets per pack
Availability: Out of stock

Kinestase (also known as cisapride) is a gastrointestinal stimulant that is used to treat gastrointestinal problems, in particular, gastroesophageal reflux illness, nighttime heartburn, and bowel constipation. It’s often prescribed to patients who do not respond well to other forms of treatment and therapies.

Kinestase is unavailable for purchase today but you can find medications with similar indications on this page.

Indications

• Prokinetic of intestinal motility;
• Gastroesophageal reflux in all its forms and ages;
• Gastroparesis of diverse origin: idiopathic or secondary;
• Functional dyspepsia;
• Non-ulcer dyspepsia;
• Poor colonic propulsive activity.

Dosage and administration

The drug is taken orally.

Adults: Depending on the intensity of the problem, the dose of Kinestase is 5 or 10 mg, administered 2 to 4 times a day, before meals. In general, 5 mg is recommended three or four times a day in cases considered mild. For the most serious cases, the dose will be 10 mg 3 to 4 times a day.

Children: The usual dose, repeated 3 to 4 times a day, is 0.2 mg/kg. The drug should be administered before meals.

Optimal therapeutic effects are usually obtained after one week. In chronic constipation, this therapeutic effect is achieved in two or more months of treatment. In renal or hepatic impairment. it is recommended to give half the daily dose.

Contraindications

• Hypersensitivity to the active substance (cisapride);
• Pregnancy and breastfeeding;
• Congestive heart failure, multiple organ failure, chronic obstructive pulmonary disease and advanced cancer;
• The concomitant use of drugs that significantly inhibit these enzymes since it can result in a significant increase in plasma levels of cisapride and increase the risk of prolongation of the QT interval. Examples of such drugs are azole antifungals, macrolide antibiotics, HIV protease inhibitors, such as ritonavir and indinavir.

It is recommended to avoid the use of Kinestase in patients with the following risk factors: cardiac arrhythmia, uncorrected electrolyte disorders (potassium/magnesium), advanced renal failure, particularly dialysis, significant chronic obstructive pulmonary disease, respiratory failure, conditions associated with prolongation of the QT interval (congenital prolonged QT syndrome, idiopathic QT prolongation, QT prolongation associated with diabetes mellitus, combination with medications known to prolong the QT interval), history of significant heart disease (including serious ventricular arrhythmia, second or third-degree atrioventricular block, congestive heart failure, ischemic heart disease).

Side effects

The drug can cause abdominal cramps, borborygmus, diarrhea, minor headache, rash, pruritus, urticaria, bronchospasm (hypersensitivity reactions) and increased urinary frequency. Rare cases of cardiac arrhythmias have been reported, including ventricular tachycardia, ventricular fibrillation, helical tachycardia and prolongation of the QT interval. Most of these patients had received multiple medications and had preexisting heart disease or risk factors for arrhythmias. Hyperprolactinemia that can cause gynecomastia and galactorrhea has also been reported.

Overdose

The symptoms that most frequently occur due to Kinestase overdose are abdominal cramps and increased frequency of bowel movements. Rare cases of prolongation of the QT interval have been reported. Mild sedation, apathy and atony have been observed in patients younger than 1 year. Treatment of overdose includes the administration of activated carbon and close observation of the patient. QT interval prolongation should be monitored, as well as factors that may predispose to the presentation of Torsade de pointes, such as hypokalemia and bradycardia.

Interaction

The increase in gastric emptying could cause a more accelerated absorption of diazepam, alcohol, anticoagulants, benzodiazepines, cimetidine and ranitidine. Cisapride does not affect the bioavailability of digoxin, tolbutamide and propranolol. Anticholinergics can antagonize the effect of cisapride on intestinal motility.